FY2025 Earnings Forecast for Amgen Inc. Issued By William Blair (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN) – Analysts at William Blair lowered their FY2025 EPS estimates for shares of Amgen in a research note issued on Wednesday, April 17th. William Blair analyst M. Phipps now expects that the medical research company will post earnings per share of $19.15 for the year, down from their previous estimate of $19.34. The consensus estimate for Amgen’s current full-year earnings is $19.45 per share.

A number of other equities research analysts also recently weighed in on AMGN. Royal Bank of Canada reiterated an “outperform” rating and issued a $329.00 target price on shares of Amgen in a report on Wednesday, April 3rd. Daiwa Capital Markets raised shares of Amgen from a “neutral” rating to a “buy” rating and increased their target price for the stock from $264.00 to $320.00 in a research note on Thursday, December 21st. Truist Financial reaffirmed a “buy” rating and issued a $320.00 price target on shares of Amgen in a research note on Friday, April 12th. Leerink Partnrs cut shares of Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Finally, UBS Group decreased their target price on Amgen from $314.00 to $284.00 and set a “neutral” rating for the company in a research report on Wednesday. Ten equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, Amgen currently has an average rating of “Moderate Buy” and an average target price of $296.95.

Amgen Stock Performance

AMGN stock opened at $262.75 on Friday. Amgen has a 1-year low of $211.71 and a 1-year high of $329.72. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. The stock has a 50-day moving average price of $277.34 and a 200-day moving average price of $281.24. The firm has a market cap of $140.81 billion, a PE ratio of 21.04, a price-to-earnings-growth ratio of 2.46 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.66 by $0.05. The business had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. Amgen’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.09 earnings per share.

Institutional Trading of Amgen

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Amgen by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock worth $13,178,910,000 after purchasing an additional 165,636 shares during the period. Morgan Stanley lifted its stake in Amgen by 12.9% in the fourth quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock valued at $3,493,471,000 after purchasing an additional 1,523,665 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Amgen by 1.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 8,819,690 shares of the medical research company’s stock worth $2,132,778,000 after buying an additional 94,565 shares during the last quarter. Moneta Group Investment Advisors LLC raised its stake in shares of Amgen by 83,875.6% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock valued at $1,980,571,000 after buying an additional 7,532,031 shares during the period. Finally, Northern Trust Corp grew its stake in shares of Amgen by 3.8% during the 3rd quarter. Northern Trust Corp now owns 6,977,625 shares of the medical research company’s stock worth $1,875,306,000 after acquiring an additional 255,463 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 3.43%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s payout ratio is 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.